Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2012-004905-29
    Sponsor's Protocol Code Number:TMC435HPC3014
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2013-06-10
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2012-004905-29
    A.3Full title of the trial
    A Phase 3, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of TMC435 plus Pegylated Interferon alfa-2a and Ribavirin Administered for 12 Weeks in Treatment-Naïve Subjects with Chronic Genotype 1 HCV Infection
    Estudio de fase III, abierto, de un solo grupo para evaluar la seguridad y eficacia de TMC435 más interferón pegilado alfa-2a y ribavirina administrado durante 12 semanas en sujetos sin tratamiento previo con infección crónica por VHC de genotipo 1
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A Study of TMC435 plus Pegylated Interferon alfa-2a and Ribavirin in Participants with Chronic HCV Infection
    A.4.1Sponsor's protocol code numberTMC435HPC3014
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorJanssen-Cilag International NV
    B.1.3.4CountryBelgium
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportJanssen-Cilag International NV
    B.4.2CountryBelgium
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationJanssen-Cilag International NV - Clinical Registry Group
    B.5.2Functional name of contact pointJanssen Biologics BV
    B.5.3 Address:
    B.5.3.1Street AddressArchimedesweg 29
    B.5.3.2Town/ cityLeiden
    B.5.3.3Post code2333CM
    B.5.3.4CountryNetherlands
    B.5.4Telephone number+31071524 2166
    B.5.5Fax number+31071524 2110
    B.5.6E-mailClinicalTrialsEU@its.jnj.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameJNJ-38733214-AAA - capsule, hard (G019)
    D.3.2Product code TMC435 (or R494617)
    D.3.4Pharmaceutical form Capsule, hard
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNsimeprevir
    D.3.9.1CAS number 923604-59-5
    D.3.9.2Current sponsor codeTMC435
    D.3.9.3Other descriptive nameSIMEPREVIR
    D.3.9.4EV Substance CodeSUB64783
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number150
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameJNJ-38733214-AAA - capsule, hard (G028)
    D.3.2Product code TMC435 (or R494617)
    D.3.4Pharmaceutical form Capsule, hard
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNsimeprevir
    D.3.9.1CAS number 923604-59-5
    D.3.9.2Current sponsor codeTMC435
    D.3.9.3Other descriptive nameSIMEPREVIR
    D.3.9.4EV Substance CodeSUB64783
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number150
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Hepatitis C Virus (HCV) genotype-1 infection
    Infección Virus Hepatitis C Genotipo-1
    E.1.1.1Medical condition in easily understood language
    Hepatitis C infection
    Infección Hepatitis C
    E.1.1.2Therapeutic area Diseases [C] - Virus Diseases [C02]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 16.0
    E.1.2Level PT
    E.1.2Classification code 10019744
    E.1.2Term Hepatitis C
    E.1.2System Organ Class 10021881 - Infections and infestations
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    - To determine the efficacy of TMC435 plus PegIFNalfa-2a and RBV when administered for 12 weeks in treatment-naïve subjects with chronic genotype 1 HCV infection, as measured by the proportion of subjects with sustained virologic response 12 weeks after planned end of treatment (SVR12).
    - To assess the safety and tolerability of TMC435 plus PegIFNalfa-2a and RBV when administered for 12 weeks in treatment-naïve subjects with the chronic genotype 1 HCV infection
    - Determinar la eficacia de TMC435 más PegIFNalfa-2a y RBV cuando se administra durante 12 semanas a pacientes no tratados previamente con infección crónica por el VHC de genotipo 1, según lo medido por la proporción de sujetos con respuesta virológica sostenida 12 semanas después del final previsto del tratamiento (RVS12).
    - Evaluar la seguridad y tolerabilidad de TMC435 más PegIFNalfa-2a y RBV cuando se administra durante 12 semanas en pacientes no tratados previamente con infección crónica por el VHC de genotipo 1
    E.2.2Secondary objectives of the trial
    See section 2.1 - Objectives - Major Secondary Objectives, p33 of the Clinical Trial Protocol
    Consulte la sección 2.1 - Objetivos - Objetivos secundarios más importantes, p33 del Protocolo del ensayo clínico
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    -treatment-naïve (previously untreated) with confirmed chronic Hepatitis C Virus (HCV) infection
    - liver biopsy performed within 2 years prior to screening or non-invasive confirmation of the liver disease stage (by transient elastography) performed within 6 months prior to screening
    -liver disease stage equivalent to Metavir Score F0-F2 (no fibrosis, or portal fibrosis without or with few septa)
    - genotype 1 HCV infection (confirmed at screening)
    - Before screening, a woman must be either not of childbearing potential: postmenopausal (> 45 years of age with amenorrhea for at least 12 months or any age with amenorrhea for at least 6 months and a serum follicle stimulating hormone (FSH) level > 40 IU/mL); permanently sterilized (e.g., tubal occlusion, hysterectomy, bilateral salpingectomy); or otherwise be incapable of pregnancy OR of childbearing potential and practicing two different highly effective methods of birth control (including at least one barrier method) consistent with local regulations regarding the use of birth control methods for participants participating in clinical studies: e.g., established use of oral, injected or implanted hormonal methods of contraception; placement of an intrauterine device (IUD) or intrauterine system (IUS); barrier methods: condom with spermicidal foam/gel/film/cream/suppository or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository; male partner sterilization (the vasectomized partner should be the sole partner for that participant); true abstinence (when this is in line with the preferred and usual lifestyle of the participant) Note: If the childbearing potential changes after start of the study (e.g., woman who is not heterosexually active becomes active, premenarchal woman experiences menarche) a woman must begin 2 highly effective methods of birth control, as described above
    - A man who is sexually active with a woman of childbearing potential and has not had a vasectomy must agree to use two different highly effective methods of birth control (including at least one barrier method). A man who is sexually active with a woman of childbearing potential and has had a vasectomy must agree to use a barrier method of birth control e.g., either condom with spermicidal foam/gel/film/cream/suppository or partner with occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository. All men must also not donate sperm during the study and for 6 months (or longer if dictated by local regulations) after the last dose of RBV
    - sin tratamiento previo con infección crónica por el virus hepatitis C (VHC) confirmada
    - biopsia de hígado realizada en los 2 años anteriores a la selección o confirmación no invasiva del estadio de la hepatopatía (por elastografía transitoria) realizada en los 6 meses anteriores a la selección;
    - hepatopatía en estadio equivalente a puntuación Metavir F0-F2 (sin fibrosis, o fibrosis portal sin septos o con pocos septos)
    - infección por VHC de genotipo 1 (confirmado en la selección).
    - Antes de la selección, la mujer debe no estar en edad fértil: posmenopáusica (> 45 años de edad con amenorrea durante al menos 12 meses o cualquier edad con amenorrea durante al menos 6 meses y una concentración de hormona foliculoestimulante (HFE) en suero > 40 UI/ml); esterilizada permanentemente (por ejemplo, la oclusión tubaria, histerectomía, salpingectomía bilateral); o incapaz de embarazo O en edad fértil y la practicando dos métodos muy eficaces diferentes de control de la natalidad (incluyendo por lo menos un método de barrera) coherente con las regulaciones locales sobre el uso de métodos anticonceptivos para los participantes en estudios clínicos: por ejemplo, el uso de métodos hormonales anticonceptivos establecidos orales, inyectados o implantados; la colocación de un dispositivo intrauterino (DIU) o un sistema intrauterino (SIU); los métodos de barrera: preservativo con espermicida en espuma/gel/película/crema/supositorio o dispositivo oclusivo (diafragma o capuchón cervical) con espermicida en espuma/gel/película/crema/ supositorio; esterilización de la pareja masculina (la pareja sometida a vasectomía debe ser la única pareja de esa participante); abstinencia verdadera (cuando esto está en consonancia con el estilo de vida preferido y habitual de la participante). Nota: Si el potencial de fertilidad cambia después del inicio del estudio (por ejemplo, una mujer que no es heterosexual activa se vuelve activa, una mujer premenárquica experimenta la menarquia) una mujer debe comenzar 2 métodos muy eficaces de control de la natalidad, como se describió anteriormente
    - Un hombre que tenga relaciones sexuales con una mujer en edad fértil y no se haya sometido a una vasectomía debe aceptar el uso de dos métodos muy eficaces diferentes de control de natalidad (incluyendo por lo menos un método de barrera). Un hombre que tenga relaciones sexuales con una mujer en edad fértil y se haya sometido a vasectomía debe comprometerse a utilizar un método anticonceptivo de barrera por ejemplo, o bien preservativos con espermicida en espuma/gel/película/crema/supositorio o pareja con dispositivo oclusivo (diafragma o capuchón cervical) con espermicida en espuma/gel/película/crema/supositorio. Ninguno de los hombres debe tampoco donar esperma durante el estudio ni durante 6 meses (o más si así lo exige la normativa local) después de la última dosis de RBV.
    E.4Principal exclusion criteria
    - Participants who have been previously exposed to anti-HCV treatment, including any approved or investigational direct-acting antiviral (DAA) therapy
    - Participant has chronic liver disease of a non-HCV etiology (including but not limited to hemochromatosis, Wilson?s disease, ?1-antitrypsin deficiency, cholangitis, drug- or alcohol-related liver disease, primary biliary cirrhosis)
    - Participant is infected with hepatitis B virus (hepatitis B surface antigen [HBsAg] positive) or human immunodeficiency virus (HIV-1 or HIV-2) (HIV-1 or HIV-2 antibody test positive at screening)
    - Participant is infected with non-genotype 1 HCV
    - Participant has advanced liver disease equivalent to Metavir status F3-F4 (bridging fibrosis or cirrhosis)
    - Los participantes que han sido expuestos previamente a un tratamiento anti-VHC, incluyendo cualquier tratamiento antiviral de acción directa (AAD), aprobado o en investigación
    – Participante que tiene hepatopatía crónica de etiología no-VHC (que incluye pero no se limita a la hemocromatosis, la enfermedad de Wilson, deficiencia de antitripsina a1, colangitis, enfermedad hepática relacionada con medicamentos o el alcohol, cirrosis biliar primaria)
    - Participante infectado por el virus de la hepatitis B (antígeno de superficie de hepatitis B [HBsAg] positivo) o virus de la inmunodeficiencia humana (VIH-1 o VIH-2) (prueba de anticuerpos contra VIH-1 o VIH-2 positiva en la selección)
    - Participante infectado con VHC no de genotipo 1
    - Participante tiene hepatopatía avanzada equivalente a la categoría Metavir F3-F4 (fibrosis en puente o cirrosis)
    E.5 End points
    E.5.1Primary end point(s)
    The number of participants with sustained virologic response 12
    weeks after planned end of treatment (SVR12).
    La proporción de participantes con respuesta virológica sostenida 12 semanas después del final previsto del tratamiento (RVS12).
    E.5.1.1Timepoint(s) of evaluation of this end point
    Week 24
    Semana 24
    E.5.2Secondary end point(s)
    - The number of participants who achieve rapid virologic response
    (RVR)
    - The number of participants who achieve virologic response at Week 2 (W2VR)
    - The number of participants with sustained virologic response 24
    weeks after planned end of treatment (SVR24)
    - The number of participants with > or = 2 log decrease in hepatitis C virus (HCV) RNA at each time point
    - The number of participants with hepatitis C virus (HCV) RNA < 25 IU/mL undetectable at each time point
    - The number of participants with viral breakthrough
    - The number of participants with viral relapse
    - Change from Baseline in the Hepatitis C Treatment Symptom &
    Impact Questionnaire (HCV SIQ) symptom and impact scores
    - Change from Baseline in The Fatigue Severity Scale (FSS) total
    score
    - Change from Baseline in The Center for Epidemiologic Studies
    Depression Scale (CES-D) score
    - Change from Baseline in The Work Productivity and Activity Index
    (WPAI) for Hepatitis C missed work time, daily activity impairment, and productivity scores
    - Change from Baseline in The EuroQol 5 Dimension (EQ5D) Visual
    Analog Scale (VAS) valuation index, and Descriptive System scores
    - The number of participants with normalized alanine aminotransferase (ALT) levels
    - Change from Screening in liver disease stage assessment
    - The number of participants reporting adverse events as a measure of safety and tolerability
    - El número de participantes que logran una respuesta virológica rápida (RVR)
    – El número de participantes que logran una respuesta virológica en la semana 2 (RV2S)
    – El número de participantes con respuesta virológica sostenida 24 semanas después del final previsto de tratamiento (RVS24)
    - El número de participantes con disminución > o = 2 log en el ARN del virus de la hepatitis C (VHC) en cada punto cronológico
    - El número de participantes con ARN del virus hepatitis C (VHC) < 25 UI/ml indetectable en cada punto cronológico
    – El número de participantes con rebrote viral
    - El número de participantes con recaída viral
    - Cambio desde el inicio en la puntuación de síntomas e impacto del Cuestionario de síntomas e impacto del tratamiento de la hepatitis C (VHC SIQ)
    - El cambio desde el inicio en la puntuación total de la escala de la gravedad y el impacto de la fatiga (FSS)
    - Cambio desde el inicio en la puntuación de la escala de depresión del Centro de Estudios Epidemiológicos (CES- D)
    - Cambio desde el inicio en el índice de tiempo perdido de trabajo y la discapacidad en las actividades diarias (Work Productivity and Activity Index, WPAI) para las puntuaciones del de tiempo perdido de trabajo y la discapacidad en las actividades diarias y pérdida de productividad por hepatitis C
    - Cambio desde el inicio en las puntuaciones de la escala EuroQol de 5 dimensiones (EQ5D), escala visual analógica (EVA), y del sistema descriptivo
    - El número de participantes con concentración normalizada de alanina aminotransferasa (ALT)
    - El cambio desde la selección en la evaluación del estadio de la enfermedad hepática
    - El número de participantes que informaron de acontecimientos adversos como una medida de la seguridad y tolerabilidad
    E.5.2.1Timepoint(s) of evaluation of this end point
    - Week 4
    - Week 2
    - Week 48
    - Up to Week 48
    - Up to Week 48
    - Up to Week 48
    - Up to Week 48
    - Day 1 and at each study visit up to Week 48
    - Day 1 and at each study visit up to Week 48
    - Day 1 and at each study visit up to Week 48
    - Day 1 and at each study visit up to Week 48
    - Day 1 and at each study visit up to Week 48
    - Up to Week 48
    - Week -6; Week 48
    - Up to Week 48
    - semana 4
    - semana 2
    - semana 48
    - Hasta la semana 48
    - Hasta la semana 48
    - Hasta la semana 48
    - Hasta la semana 48
    - Día 1 y en cada visita del estudio hasta la semana 48
    - Día 1 y en cada visita del estudio hasta la semana 48
    - Día 1 y en cada visita del estudio hasta la semana 48
    - Día 1 y en cada visita del estudio hasta la semana 48
    - Día 1 y en cada visita del estudio hasta la semana 48
    – Hasta la semana 48
    - semana 6; semana 48
    - Hasta la semana 48
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic Yes
    E.6.12Pharmacoeconomic No
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    Tolerability
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned4
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA29
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA No
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years1
    E.8.9.1In the Member State concerned months2
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years1
    E.8.9.2In all countries concerned by the trial months2
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 146
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 4
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state30
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 150
    F.4.2.2In the whole clinical trial 150
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    None
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2013-08-09
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2013-07-05
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2015-08-30
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 04 08:08:56 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA